MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients : A Phase IIa, Double-Blind, Randomized, Multi-Center Study Comparing MRG-001 to Placebo in Patients With Acute Respiratory Distress Syndrome
This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS.The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ClinicalTrials.gov - (2024) vom: 13. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: March 13, 2024, Last downloaded: ClinicalTrials.gov processed this data on March 20, 2024, Last updated: March 20, 2024 |
|---|
| Study ID: |
NCT06308926 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG000109819 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG000109819 | ||
| 003 | DE-627 | ||
| 005 | 20240320010428.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG000109819 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT06308926 | ||
| 035 | |a (UBBS_Klinische_Studien)MRG23ARDS | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients |b A Phase IIa, Double-Blind, Randomized, Multi-Center Study Comparing MRG-001 to Placebo in Patients With Acute Respiratory Distress Syndrome |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: March 13, 2024, Last downloaded: ClinicalTrials.gov processed this data on March 20, 2024, Last updated: March 20, 2024 | ||
| 520 | |a This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS.The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges. | ||
| 650 | 2 | |a Respiratory Distress Syndrome | |
| 650 | 2 | |a Respiratory Distress Syndrome, Newborn | |
| 650 | 2 | |a Respiratory Insufficiency | |
| 650 | 2 | |a Acute Lung Injury | |
| 650 | 2 | |a Respiratory Tract Diseases | |
| 650 | 2 | |a Syndrome | |
| 650 | 2 | |a Cytokine Release Syndrome | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Not yet recruiting | |
| 650 | 4 | |a Phase: Phase 2 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 13. März |
| 773 | 1 | 8 | |g year:2024 |g day:13 |g month:03 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT06308926 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 13 |c 03 | ||